Background: Delirium is associated with increased morbidity and mortality. The fac-
| BACKGROUND
Delirium is the most common neuropsychiatric disorder, affecting 15%-60% of hospitalized general medical and surgical patients and up to 87% of mechanically ventilated patients in the intensive care unit (ICU). 1 In critically ill patients, the presence of delirium is associated with worse mortality, increased rates of self-extubation and prolonged duration of mechanical ventilation, increased ICU and hospital length of stay (LOS), and greater hospital costs. [2] [3] [4] [5] Moreover, not only premorbid cognitive dysfunction is a risk factor for delirium, but delirium also has further lasting negative effects on cognitive function. 6, 7 As delirium has been associated with worse survival and outcomes in other critically ill 3 and transplant populations, 8 it could be expected to have a similar effect in lung transplant recipients. The available data on delirium after lung transplantation are limited to a few small single-center studies. [9] [10] [11] A retrospective study of 30 lung transplant recipients found that 73% of patients developed delirium in the first 2 weeks after transplantation. 9 In this sample, factors associated with an increased risk of delirium included use of cardiopulmonary bypass, higher cyclosporine levels, and relocation to await surgery. 9 A prospective study of 21 lung transplant recipients found a delirium incidence of 19% within 96 hours of surgery, which was associated with an increased time to extubation. 10 A recent prospective study of 63 lung transplant recipients found a delirium incidence of 37%, mostly in the immediate postoperative period, determined with the Confusion Assessment Method (CAM) screening tool. 11 Worse preoperative cognitive functioning was associated with delirium occurrence, while the presence and duration of delirium were both associated with longer hospital stays. 11 In addition, lower cerebral perfusion pressure was found to be associated with doubling the risk of delirium in the same patient sample, as well as increasing the duration and severity of delirium. 12 Finally, delirium during the index hospitalization in lung transplant recipients without cystic fibrosis has been associated with worse post-transplant neurocognitive function. 13 The purpose of our study was to determine the incidence of delirium in a large lung transplant population, identify predictors associated with the development of delirium, including postoperative sedative and pain medication use, and characterize delirium impact on hospital resource utilization and clinical outcomes, including mortality.
Characterization of the recipient-level associations with delirium could
help identify patients at high-risk and focus delirium screening and prevention interventions. 
| METHODS

| Statistical analysis
Characteristics of recipients with and without delirium (early-onset and ever-onset) were compared using the chi-square test or The study was performed in a cardiothoracic ICU at Stanford Hospital.
Patients were roomed either in double or single rooms. Nonpharmacological measures were used throughout the ICU and applied to all patients according to our hospital protocol to prevent emergence of delirium (eg, frequent orientation, sleep-wake cycle regulation, early mobilization).
| RESULTS
| Delirium demographics and characteristics
Of 164 lung recipients transplanted within the study period, 163 patients met inclusion criteria. The average patient's age was 50. The median time to onset of postoperative delirium was 2 days (mean 4.0 days, SD 4.2 days) with a median duration of 4.5 days (IQR 3, 7.5) (mean duration 6.9 days, SD 6.6 days).
The characteristics of recipients with and without early-onset or ever-onset delirium are shown in Table 1 . Recipients with early-onset delirium were more likely to be obese (BMI>30) and less likely to be underweight (BMI<20) compared to those without delirium (P=.008).
There were no other significant differences in baseline characteristics between recipients with and without early-onset delirium. Recipients with ever-onset delirium were again more likely to be obese and less likely to be underweight (P=.004) and had longer cardiopulmonary bypass time (P=.011) than those who never developed hospital delirium.
| Recipient characteristics and post-transplant medications associated with delirium
In univariate logistic regression analysis, age, gender, underlying diag- CI: 1.07-4.89) were associated with early-onset delirium.
| Delirium, hospital resource use, and mortality
The unadjusted outcomes between recipients with and without delirium are shown in Table 2 .
T A B L E 1 Characteristics of lung transplant recipients with and without delirium In unadjusted comparison, delirium was associated with longer duration of mechanical ventilation and length of stay. After adjusting for recipient and transplant characteristics, early-onset delirium was associated with a longer adjusted ventilator duration (P=.001), ICU LOS (P<.001), and hospital LOS (P=.005) in those with early-onset delirium.
The development of ever-onset delirium during post-transplant hospitalization was associated with both an increase in ICU (P<.001) and total hospital LOS (P<.001).
Unadjusted one-year survival was worse in those with early-onset delirium (P=.026) and ever-onset delirium (P=.027) than those without delirium (Figures 1 and 2 ). However, after adjusting for recipient variables, early-onset delirium (adjusted HR 1.65, 95% CI: 0.67-4.03) and ever-onset delirium (adjusted HR 1.70, 95% CI: 0.63-4.55) were not associated with one-year survival.
| DISCUSSION
The results of our study, analyzing delirium in the largest published recipient sample to date, support and expand upon previously published findings on the delirium incidence and predictors in lung transplant recipients. As in previous studies, [9] [10] [11] we found that delirium is common in this population, occurring in over 40% of lung transplant recipients, and is associated with worse medical outcomes. We confirmed the previously described association between post-lung transplant delirium and prolonged hospital stay, but also identified increased ventilation duration, and prolonged ICU stay post-lung transplantation.
Additionally, we found that recipient obesity, classified as BMI>30, and bolused benzodiazepines use within first postoperative day are associated with an increased risk for delirium.
Prolonged hospital stay has been previously demonstrated in ICU 2 and in lung transplant recipients 11 who experience delirium. We found that early-onset and ever-onset delirium are associated with longer ICU and hospital stays. ICU and hospital LOS are closely monitored metrics in organ transplantation, and shorter LOS is considered an important factor in reducing lung transplant cost and post-transplant morbidity. 18 Thus, delirium prevention measures and early and routine screening for delirium in lung transplant recipients directed at facilitating the prompt identification and treatment of this complication may constitute an important intervention which may translate into decreased morbidity, shorter hospital stays, and decreased care costs.
Benzodiazepines are an established risk factor for development of delirium in ICU patients, 19 and our results similarly demonstrate a significant association between intermittent benzodiazepine use and early-onset delirium in lung transplant recipients. Notably, the use of benzodiazepine or dexmedetomidine infusions for postoperative sedation and comfort had no influence on the development of early-onset delirium in this study. We contribute this finding to the standardization F I G U R E 1 One-year lung transplant recipient survival by presence of early-onset delirium. Unadjusted one-year survival is shown for lung transplant recipients with early-onset of delirium (dashed line) and for those without early-onset delirium (solid line) F I G U R E 2 One-year lung transplant recipient survival by presence of ever-onset delirium. Unadjusted one-year survival is shown for lung transplant recipients with ever-onset of delirium (dashed line) and for those without ever-onset delirium (solid line) of our post-lung transplant ICU order set that preferentially selects for dexmedetomidine infusion (total of 68.1% of patients received this on the first day) and discourages benzodiazepine infusions (only 7.36% of patients received this on the first day). Dexmedetomidine has been demonstrated to be protective against development of delirium in prior randomized controlled trials, 20 while benzodiazepines have been demonstrated to be deleterious for delirium development. 19 However, there was greater variability in the use of intermittent benzodiazepines with 28.77% of lung transplant recipients receiving a bolus within the first postoperative day. Our finding supports that overall avoidance of benzodiazepines should be encouraged and could potentially reduce the incidence of early-onset delirium in lung transplant recipients.
Further prospective work is needed to test whether benzodiazepine avoidance and/or other behavioral or medication-related interventions can modify the incidence of delirium in lung transplant recipients.
The finding of higher BMI associated with early-onset delirium in lung transplant recipients is novel. Previous study of pretransplant predictors in lung transplant recipients did not include BMI. 11 On the contrary, lower BMI has been shown to be associated with the development of delirium in other surgical populations, such as gastrointestinal surgery, 21 total knee arthroplasty, 22 and hip fracture repair 23 patients. It has been postulated that low BMI might represent low nutritional status and inflammation facilitating development of delirium. However, in our study of lung transplant population, the opposite effect was seen with high BMI (>30) significantly associated with the development of delirium. Obesity is an established independent risk factor for the development of primary graft dysfunction (PGD) after lung transplantation. 24, 25 However, we found that obesity remained independently associated with risk for delirium even after adjusting for the presence of PGD at 48 or 72 hours. Notably, obesity has been associated with increased incidence of sternal wound infections, prolonged ventilation, and increased rate of renal failure in cardiothoracic surgeries. 26, 27 These complications can also lead to development of delirium in surgical populations. In any case, our findings suggest that obesity may need to be addressed prior to lung transplantation, and that these patients should be considered at higher risk for the development of delirium and thus require additional surveillance after transplantation.
Finally, we found an association between unadjusted mortality and development of delirium, which ceased to be statistically significant after adjustment for other clinical factors. Larger prospective studies are needed to further characterize this potential association. Studies on delirium in other populations have demonstrated that delirium is independently associated with increased mortality. As the median survival of lung transplant recipients is 5.7 years, 28 any interventions, such as delirium prophylaxis, aimed at potentially improving this outcome, could prove advantageous in improving graft outcomes.
This study has several limitations. First, the retrospective identification of delirium based upon chart analysis limits the accuracy of delirium incidence. 16 It is possible that cases of hypoactive delirium were under-recognized, as they are less likely to be identified and/or recorded by most ICU providers. 29, 30 Similarly, it is also possible that hyperactive delirium was over-diagnosed as agitation due to physical discomfort can be mistaken for agitation in delirium. Yet, the rate of delirium in our sample is similar to that reported by Smith et al. in prospectively followed lung recipients. 11 In addition, the diagnosis of delirium based on the whole chart extraction has been previously reported to have good sensitivity (74%) and specificity (83%), when compared to reference standard interviewer ratings for delirium based on the widely used and validated Confusion Assessment Method (CAM). 15 Second, the abstraction of medication dosages had its limitations. While we were able to obtain the exact dosages of intermittent medications, we could only obtain binary (present/absent) data on the continuously infused medications. Thus, in our analyses we had to separate opiates and benzodiazepines based on whether they were administered via infusion (only binary data) or via intermittent boluses (exact dosages). Third, the absence of recipient's pretransplant cognitive status data prevented us from controlling for this variable. Finally, we were limited by the study design in establishing a causal relationship between recipient characteristics or medications used and delirium. Future prospective studies are needed to further characterize patients at risk for delirium, determine associations of administered medications and development of delirium, and carefully evaluate and test the effect of interventions on delirium in lung transplant recipients.
| CONCLUSIONS
Delirium is common among lung transplant recipients occurring in 44.2% of patients during the initial post-transplant hospitalization.
Recipients who are obese (BMI>30) and who receive benzodiazepine 
